{"id":"sgx301-synthetic-hypericin","safety":{"commonSideEffects":[{"rate":null,"effect":"Photosensitivity/phototoxicity"},{"rate":null,"effect":"Skin irritation at treatment site"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Pain or burning at application site"}]},"_chembl":{"chemblId":"CHEMBL286494","moleculeType":"Small molecule","molecularWeight":"504.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hypericin is a naturally occurring photosensitizer that, when activated by visible light, produces singlet oxygen and other reactive oxygen species that cause direct cytotoxic damage to cells. SGX301 is a synthetic formulation designed to improve the pharmacokinetic properties and therapeutic efficacy of hypericin for use in photodynamic therapy, enabling selective destruction of diseased tissue while minimizing systemic toxicity.","oneSentence":"SGX301 is a synthetic hypericin that generates reactive oxygen species upon light activation to destroy targeted cells, particularly in photodynamic therapy applications.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:34:08.822Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cutaneous T-cell lymphoma (mycosis fungoides)"},{"name":"Other dermatologic malignancies and lesions amenable to photodynamic therapy"}]},"trialDetails":[{"nctId":"NCT05872854","phase":"PHASE2","title":"Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light","status":"COMPLETED","sponsor":"Ellen Kim, MD","startDate":"2023-08-21","conditions":"Cutaneous T Cell Lymphoma, Mycosis Fungoides","enrollment":10},{"nctId":"NCT06149247","phase":"PHASE2","title":"HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL","status":"COMPLETED","sponsor":"Soligenix","startDate":"2023-12-05","conditions":"Cutaneous T-Cell Lymphoma/Mycosis Fungoides","enrollment":10},{"nctId":"NCT05380635","phase":"PHASE2","title":"PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma","status":"COMPLETED","sponsor":"Soligenix","startDate":"2022-05-09","conditions":"Cutaneous T-Cell Lymphoma/Mycosis Fungoides","enrollment":9},{"nctId":"NCT02448381","phase":"PHASE3","title":"FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)","status":"COMPLETED","sponsor":"Soligenix","startDate":"2015-12","conditions":"Cutaneous T-Cell Lymphoma","enrollment":169}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hypericin","Synthetic Hypericin"],"phase":"phase_3","status":"active","brandName":"SGX301 (synthetic hypericin)","genericName":"SGX301 (synthetic hypericin)","companyName":"Soligenix","companyId":"soligenix","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SGX301 is a synthetic hypericin that generates reactive oxygen species upon light activation to destroy targeted cells, particularly in photodynamic therapy applications. Used for Cutaneous T-cell lymphoma (mycosis fungoides), Other dermatologic malignancies and lesions amenable to photodynamic therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}